{
    "clinical_study": {
        "@rank": "45223", 
        "arm_group": [
            {
                "arm_group_label": "A", 
                "arm_group_type": "Experimental", 
                "description": "Ticagrelor 90 mg as a whole tablet"
            }, 
            {
                "arm_group_label": "B", 
                "arm_group_type": "Experimental", 
                "description": "Ticagrelor 90 mg tablet crushed and suspended in water"
            }, 
            {
                "arm_group_label": "C", 
                "arm_group_type": "Experimental", 
                "description": "Dispersed ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the the stomach"
            }
        ], 
        "brief_summary": {
            "textblock": "Study to investigate if the uptake of Ticagrelor into the body differs depending on method\n      of administration."
        }, 
        "brief_title": "Study to Investigate if the Uptake of Ticagrelor Into the Body Differs Depending on Method of Administration.", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Bioavailability Heathy Volunteers", 
        "detailed_description": {
            "textblock": "Study to evaluate the bioavailability of the crushed ticagrelor tablets when administered\n      orally or through nasogastric tubes compared to whole ticagrelor tablets given orally"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and female volunteers aged 18 to 50 years (inclusive) with suitable\n             veins for cannulation or repeated venepuncture\n\n          -  Have a body mass index  between 18 and 30 kg/m2 (inclusive) and weigh at least 50 kg\n             (110 pounds [lbs]) and no more than 100 kg (220 lbs).\n\n          -  Provision of signed and dated, written informed consent prior to any study specific\n             procedures\n\n        Exclusion Criteria:\n\n          -  History of any clinically significant disease or disorder which, in the opinion of\n             the Investigator, may either put the volunteer at risk because of participation in\n             the study, or influence the results or the volunteer's ability to participate in the\n             study\n\n          -  History of haemophilia, von Willebrand's disease, lupus anticoagulant or other\n             diseases/syndromes that can either alter or increase the propensity for bleeding\n\n          -  A personal history of vascular abnormalities including aneurysms; a personal history\n             of severe haemorrhage, haematemesis, melena, haemoptysis, severe epistaxis, severe\n             thrombocytopenia, intracranial haemorrhage; or rectal bleeding within 3 months prior\n             to the screeening visit; or history suggestive of peptic ulcer disease\n\n          -  History of frequent and/or significant nose bleed or clinically significant non\n             traumatic bleed, bruise/haematoma or any other clinically significant bleeding risk,\n             as judged by the Investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01887626", 
            "org_study_id": "D5130C00076"
        }, 
        "intervention": [
            {
                "arm_group_label": "A", 
                "description": "Ticagrelor 90 mg whole tablet administered as a single oral dose", 
                "intervention_name": "Ticagrelor 90 mg whole tablet", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "B", 
                "description": "Ticagrelor 90 mg crushed and suspended in water", 
                "intervention_name": "Ticagrelor 90 mg tablet crushed", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "C", 
                "description": "Dispersed 90 mg ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the stomach", 
                "intervention_name": "Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ticagrelor", 
                "Adenosine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Phase 1, pharmacokinetic, safety, Ticagrelor", 
        "lastchanged_date": "September 17, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom"
                }, 
                "name": "Research Site"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open-label, Randomised, 3-period, 3-treatment, Crossover, Single-centre, Single-dose, Bioavailability Study With Alternative Methods of Administration of Crushed Ticagrelor Tablets, 90 mg, Compared to Whole Ticagrelor Tablets, 90 mg, in Healthy Volunteer", 
        "overall_official": [
            {
                "affiliation": "AstraZeneca, Wilmington, US", 
                "last_name": "Judith Hsia, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "AstraZeneca M\u00f6lndal, Sweden", 
                "last_name": "Mirjana Kujacic, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Quintiles London, United Kingdom", 
                "last_name": "Saeed Kahn, MBBS", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Description of the pharmacokinetic(PK) profile in terms of plasma concentration-time curve (AUC) of ticagrelor", 
                "safety_issue": "No", 
                "time_frame": "PK samples will be collected pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours post-dose"
            }, 
            {
                "measure": "Description of the pharmacokinetic(PK) profile in terms of AUC of the active metabolite of ticagrelor", 
                "safety_issue": "No", 
                "time_frame": "PK samples will be collected pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours post-dose"
            }, 
            {
                "measure": "Description of the pharmacokinetic(PK) profile in terms of maximum plasma concentration (Cmax) of ticagrelor", 
                "safety_issue": "No", 
                "time_frame": "PK samples will be collected pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours post-dose"
            }, 
            {
                "measure": "Description of the pharmacokinetic(PK) profile in terms of Cmax of the active metabolite of ticagrelor", 
                "safety_issue": "No", 
                "time_frame": "PK samples will be collected pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours post-dose"
            }
        ], 
        "removed_countries": {
            "country": "India"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01887626"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Description of the safety profile in terms of  adverse events (AE)", 
                "safety_issue": "Yes", 
                "time_frame": "From first dose through to the follow-up visit."
            }, 
            {
                "measure": "Description of the safety profile in terms of  laboratory variables", 
                "safety_issue": "Yes", 
                "time_frame": "Safety labs at screening, Day -1, Day 3 (48 hours after treatment) and follow-up"
            }, 
            {
                "measure": "Description of the safety profile in terms of vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "Vital signs at screening, pre-dose, 1 h, 3, 6, 12 and 24 hours post-dose, Day 3 for all treatment periods and follow-up"
            }, 
            {
                "measure": "Description of the safety profile in terms of physical examination findings", 
                "safety_issue": "Yes", 
                "time_frame": "Physical examination at screening, pre-dose, Day 3 and follow-up"
            }, 
            {
                "measure": "Description of the safety profile in terms of Electrocardiogram (ECG)", 
                "safety_issue": "Yes", 
                "time_frame": "ECGs at screening, Day 3 and follow-up"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}